Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00624390 · ClinicalTrials.gov registry record · NA
Sepraspray™ Laparoscopic Myomectomy Study
A NA study of Laparoscopic Myomectomy, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- NA
- Development phase
- 41
- Enrollment target
- 3
- Study locations
NCT00624390: Completed NA study of Laparoscopic Myomectomy, sponsored by Genzyme, a Sanofi Company.
NCT00624390 is a NA study of Laparoscopic Myomectomy that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 41 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00624390, a NA study of Laparoscopic Myomectomy, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- NA
- Development phase
- 41 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this research study is to obtain preliminary data of the safety and effectiveness of Sepraspray in a limited number of patients who are under going a laparoscopic myomectomy. Sepraspray will be applied to the organs in the pelvic cavity following laparoscopic myomectomy. We will compare treatment with Sepraspray as a adhesion prevention barrier after laparoscopic myomectomy versus no adhesion barrier.
Conditions Studied
Interventions
- DEVICE Sepraspray
Study Locations (3)
Illinois
- - Naperville
Pennsylvania
- - Philadelphia
Texas
- - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2007-11 |
| Est. Completion | 2008-12 |
| Phase | NA |
What the finished NCT00624390 record still lists
NCT00624390 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Laparoscopic Myomectomy appearing as the primary indexed condition, and to 1 intervention - of which Sepraspray is the first listed.
NCT00624390 reports a single indexed study location in Illinois, Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT00624390 about?
NCT00624390 is a clinical study titled "Sepraspray™ Laparoscopic Myomectomy Study". The purpose of this research study is to obtain preliminary data of the safety and effectiveness of Sepraspray in a limited number of patients who are under going a laparoscopic myomectomy. Sepraspray will be applied to the organs in the pelvic cavity following laparoscopic myomectomy. We will compa...
What is the current status of trial NCT00624390?
This trial is currently completed. It is a NA study. The enrollment target is 41 participants. The study started on 2007-11. Estimated completion is 2008-12.
What conditions does trial NCT00624390 study?
This clinical trial studies the following conditions: Laparoscopic Myomectomy.
What interventions are being tested in trial NCT00624390?
The interventions under investigation include: Sepraspray (DEVICE).
Who is sponsoring clinical trial NCT00624390?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00624390 being conducted?
This trial has 3 study locations across Illinois, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00624390's enrollment target sits among peer trials
41 1446th of 2000 higher than 554 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia